Notably, one study focusing on elderly patients, including those over 70-years-old, demonstrated favorable efficacy and safety outcomes, with a notable achievement of an 82% objective response rate (ORR) and a segment of 40% patients achieving a status of very good partial response (VGPR) or higher.33 GPRC5D, highly expressed on myeloma cells, exhibited 71-100% remission rates in several Phase I studies of GPRC5D CAR-T cells for MM treatment.16 The CS1 CAR-T cells display anti-MM activity in vitro and in murine xenograft models. This evidence concerns the gene SLAMF7 and Miyoshi myopathy.